Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update

Cognition Therapeutics reported Q3 2026 financial results with a net loss of $4.1 million. The company achieved FDA alignment on primary endpoints for a Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies and received a patent for a novel crystalline form expiring in 2045. With $31.5 million in cash and $18.2 million in grant funds, the company estimates sufficient funding into Q4 2027. Top-line results from the Phase 2 START Study in Alzheimer's disease are anticipated in H2 2027.